<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04823962</url>
  </required_header>
  <id_info>
    <org_study_id>Repogel-01</org_study_id>
    <nct_id>NCT04823962</nct_id>
  </id_info>
  <brief_title>Effect of rhGM-CSF on the Healing of Venous Leg Ulcers</brief_title>
  <official_title>Effect of Topical rhGM-CSF on the Healing of Venous Leg Ulcers: a Randomized, Placebo-controlled, Double-blind, Clinical Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reponex Pharmaceuticals A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reponex Pharmaceuticals A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to examine whether local administration of the growth factor&#xD;
      rhGM-CSF incorporated into a hydrogel, can accelerate wound healing when applied to venous&#xD;
      leg ulcers, and whether this is safe.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, placebo-controlled and double-blind, phase II clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients reaching a 40% ulcer area reduction, or more, 4 weeks after initiation of the study drug treatment/placebo</measure>
    <time_frame>4 weeks after initiation of the study drug treatment/placebo</time_frame>
    <description>Ulcer size (area in cm2) will be assessed on the randomization day (Day 0; initiation of the study drug treatment/placebo) and at the end of the study drug/placebo treatment (D28+1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change of the ulcer area</measure>
    <time_frame>4 and 8 weeks after randomization</time_frame>
    <description>The ulcer size is compared in terms of change in cm2 from the randomization day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change of the ulcer area</measure>
    <time_frame>4 and 8 weeks after randomization</time_frame>
    <description>The ulcer size is compared in terms of percentage change from the randomization day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete ulcer healing</measure>
    <time_frame>4 and 8 weeks after randomization</time_frame>
    <description>Number of subjects reaching complete ulcer healing; Full epithelization and no drainage of wound fluid or dressing requirements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete ulcer healing</measure>
    <time_frame>Through study completion (8 weeks)</time_frame>
    <description>Time to complete ulcer healing in days, with the randomization day as baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement of the wound healing process</measure>
    <time_frame>4 and 8 weeks after randomization</time_frame>
    <description>Semi-quantitatively measured (major improvement, minor improvement, status quo or worsening)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the safety profile</measure>
    <time_frame>Throughout the trial (8 weeks)</time_frame>
    <description>All clinical and laboratory adverse events will be assessed and recorded.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory measurement: Changes in the levels of cytokines and growth factors in the wound fluid</measure>
    <time_frame>Wound fluid is collected at three time points: Before initiation of the study drug/placebo (Day 0), after two weeks of treatment (Day 14) and at the end of the treatment period (Day 28).</time_frame>
    <description>Changes in the levels of each cytokine and growth factor will be quantified over time</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory measurement: Wound status</measure>
    <time_frame>Throughout the trial (8 weeks)</time_frame>
    <description>Degree of inflammation, granulation tissue, necrosis/slough, exudation and infection. Semi-quantitatively measured.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory measurement: Changes in the microbiome (number of viable bacteria)</measure>
    <time_frame>Before initiation of study drug and after two weeks of treatment</time_frame>
    <description>Assessed by the colony-forming unit (CFU)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhGM-CSF (molgramostim) + hydrogel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hydrogel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhGM-CSF + hydrogel</intervention_name>
    <description>The active substance: molgramostim (rhGM-CSF)</description>
    <arm_group_label>GM-CSF</arm_group_label>
    <other_name>Repogel</other_name>
    <other_name>Molgramostim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo hydrogel</intervention_name>
    <description>Placebo hydrogel</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Compression therapy and neutral dressings</description>
    <arm_group_label>GM-CSF</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women aged aged 18 years or older&#xD;
&#xD;
          2. Patients with at least one difficult-to-heal venous leg ulcer on standard care&#xD;
             (diagnosed by clinical evaluation) localized between the knee and ankle, including the&#xD;
             perimalleolar area.&#xD;
&#xD;
          3. Venous insufficiency confirmed by a venous Doppler/duplex ultrasound scan. A previous&#xD;
             scan before randomization can be used. If there is no previous adequate scanning, a&#xD;
             new scanning has to be performed before randomization.&#xD;
&#xD;
          4. Ulcer size 2-75 cm2 at randomization day (D0), the upper limit being defined as the&#xD;
             largest ulcer in size that fits the area selection criteria&#xD;
&#xD;
          5. Ulcer duration ≥2 months and ≤3 years&#xD;
&#xD;
          6. Negative p-HCG for women of childbearing potential&#xD;
&#xD;
          7. Patient able to understand Danish&#xD;
&#xD;
          8. Patient able to comply with the protocol&#xD;
&#xD;
          9. Patient fully informed about the study and having given written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Characteristics of the index ulcer:&#xD;
&#xD;
               1. Exposed bone, tendon, ligament, cartilage, joint or muscle&#xD;
&#xD;
               2. Cellulitis or clinical ulcer infection at the screening day D-4, or the day of&#xD;
                  randomization, D0.&#xD;
&#xD;
               3. Ulcers adjacent to the index ulcer that could interfere with the index ulcer, as&#xD;
                  judged by investigator&#xD;
&#xD;
          2. Patients that are unsuitable for the compression therapy used in the study&#xD;
&#xD;
          3. Known allergy towards GM-CSF, excipients or any other substances or remedies used in&#xD;
             the trial.&#xD;
&#xD;
          4. Vascularization: Ankle-brachial index ≤0.7&#xD;
&#xD;
          5. Active or history of following diseases:&#xD;
&#xD;
               1. Cancer (past history of well-treated cancer is however accepted after a control&#xD;
                  period of more than two years).&#xD;
&#xD;
               2. Following autoimmune diseases: rheumatoid arthritis, autoimmune thrombocytopenia,&#xD;
                  thyroiditis, psoriasis, nephritis or multiple sclerosis.&#xD;
&#xD;
               3. Lower extremity deep venous thrombosis within the last 3 months&#xD;
&#xD;
          6. Any of following active diseases:&#xD;
&#xD;
               1. Serious heart disease, including unstable angina pectoris, a major cardiac event&#xD;
                  such as myocardial infarction, congestive heart failure NYHA class III-IV within&#xD;
                  3 months before the study&#xD;
&#xD;
               2. Neutrophilic dermatoses (e.g. pyoderma gangrenosum and Sweet's syndrome)&#xD;
&#xD;
               3. Severe renal-, hepatic or pulmonary insufficiency or severely dysregulated&#xD;
                  diabetes, as judged by investigator&#xD;
&#xD;
               4. Myeloproliferative diseases and hematologic diseases (e.g. myelodysplastic&#xD;
                  syndrome and leukemia). Anemia due to chronic infection or due to deficiency of&#xD;
                  iron, B12 or folic acid is accepted if Hb &gt;5 mmol/L).&#xD;
&#xD;
               5. Significant dementia&#xD;
&#xD;
          7. Biochemistry with clinically significant abnormalities that could preclude study&#xD;
             participation as judged by the investigator, such as:&#xD;
&#xD;
               1. eGFR &lt;20 mL/min/1.73 m2&#xD;
&#xD;
               2. Hb &lt;5 mmol/L&#xD;
&#xD;
               3. ALAT &gt;1.5 x upper limit of normal value&#xD;
&#xD;
               4. Albumin &lt; 20 g/l&#xD;
&#xD;
          8. Prohibited therapy:&#xD;
&#xD;
               1. Systemic immunosuppressive treatment, immunomodulators, cytotoxic chemotherapy&#xD;
                  (exception: usage of corticosteroids) on D-4 or D0.&#xD;
&#xD;
               2. Corticosteroids with a daily dose equivalent to &gt;10 mg of prednisolone per day on&#xD;
                  D-4 or D0.&#xD;
&#xD;
               3. Topical corticosteroids in the index ulcer bed or within 1 cm of the ulcer edge&#xD;
                  on D-4 or D0.&#xD;
&#xD;
               4. Biologics within 3 months of D-4 (anti-VEGF treatment in the eye in e.g.&#xD;
                  diabetics is however allowed).&#xD;
&#xD;
          9. Weight &lt;50 kg or BMI &gt;50&#xD;
&#xD;
         10. Participation in another clinical trial&#xD;
&#xD;
         11. Planned surgery or hospitalization during trial&#xD;
&#xD;
         12. Pregnant or lactating woman. Positive pregnancy test during run-in.&#xD;
&#xD;
         13. Failure to agree to using an adequate method of contraception (having a failure rate&#xD;
             of &lt; 1% per year) throughout the study period for heterosexually active males and&#xD;
             females of childbearing potential, or disagreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse). A woman is considered to be of childbearing potential if&#xD;
             she is post-menarche and:&#xD;
&#xD;
               1. Has not reached a postmenopausal state (≥60 years of age and amenorrhea for at&#xD;
                  least ≥12 months with no identified cause other than menopause, and has not&#xD;
                  undergone surgical sterilization: removal of ovaries and/or uterus) - OR&#xD;
&#xD;
               2. No menses for over a year and confirmed by follicle-stimulating hormone (FSH)&#xD;
                  levels elevated into the postmenopausal range Examples of contraceptive methods&#xD;
                  with a failure rate of &lt;1% per year includes bilateral tubal ligation, male&#xD;
                  sterilization, proper use of hormonal contraceptives, hormone-releasing&#xD;
                  intrauterine devices and copper intrauterine devices. Male participants must be&#xD;
                  abstinent or use a condom during the trial period.&#xD;
&#xD;
         14. Blood or sperm donation during trial&#xD;
&#xD;
         15. Patient has previously been randomized in this study (rescreening is accepted&#xD;
             otherwise)&#xD;
&#xD;
         16. Judgment by the investigator that the patient is not suited for study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewa A Burian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology and Copenhagen Wound Healing Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ewa A Burian, MD</last_name>
    <phone>+45 53609159</phone>
    <email>ewa.anna.burian@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Dermatology and Copenhagen Wound Healing Center, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa A Burian, MD</last_name>
      <phone>+45 53609159</phone>
      <email>ewa.anna.burian@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Ewa A Burian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 6, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Reponex Pharmaceuticals A/S</investigator_affiliation>
    <investigator_full_name>Ewa Anna Burian</investigator_full_name>
    <investigator_title>Prinicipal Investigator, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molgramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

